Winter 2014 2015

I have in mind a prospective clinical trial in which I study a common children’s phenomenon, detailing the differences between genders, location, ethnicity, biometrics, dental data, monetary value, etc. It’s a common phenomenon that most parents have photos of and have experienced ourselves. I’m... more

5
Average: 5 (1 vote)

This issue sponsored by the Southeast Lipid Association Featuring: "Translating Clinical Trial Evidence into Practical Medicine" and "Guidelines for the Guidelines — Impact and Controversies" more

5
Average: 5 (2 votes)

Atherogenic lipoproteins play a critical role in the initiation and progression of vascular atherosclerosis, and decades of research have clearly demonstrated the benefits of lipid-lowering therapy for prevention of atherosclerotic cardiovascular disease (ASCVD) events. However, despite the... more

0
No votes yet

Case: The patient was a 62-year-old Caucasian woman when she was first seen at the Florida Lipid Institute in 2010. She had hypertension that was treated with losartan/HCTZ. She had no other significant past medical history. She had a family history of hypertension and diabetes and one brother... more

0
No votes yet

It was an honor and privilege for the Southeast Lipid Association (SELA) to host the National Lipid Association (NLA) Scientific Sessions in Orlando, Fla. this past May 2014. Excellent topics and presenters offered practical knowledge for integrating the latest clinical research guidelines into... more

0
No votes yet

“Security is mostly a superstition. It does not exist in nature, nor do the children of men as whole experience it. Avoiding danger is no safer in the long run than outright exposure. Life is either a daring adventure or nothing.” – Helen Keller This quote is a favorite of Deborah S. Croy, DNP.... more

0
No votes yet

I hope everyone had a wonderful Holiday Season and a Happy New Year! To kick off the New Year, the Foundation of the National Lipid Association (FNLA) is hard at work with new projects and partnerships. Most recently, the FNLA collaborated with Sanofi US and Regeneron Pharmaceuticals Inc. in... more

0
No votes yet

Greetings, National Lipid Association members! I hope this holiday season has been a joyous one. As we look back on 2014, we can reflect on the many accomplishments the NLA has put forth. And, as we look toward the New Year, we are encouraged for what’s to come — both for the NLA as a... more

0
No votes yet

I am honored and excited to serve as President of the Southeast Lipid Association (SELA). My passion for lipids heralds back to the formation of the Florida Lipid Associates in 1994, led by Paul Ziajka, MD, PhD, FNLA, and some others interested in lipid research and treatment. It has been... more

0
No votes yet

I write this with the holiday season having just passed us. As I sit back and reflect on the past year, it occurs to me that we have much to be thankful for! This past year we embraced the extensive statin safety report from the National Lipid Association. This was followed in September by the... more

0
No votes yet